Switch theme
Sign up to access all valuation multiples
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
2019
730
LTM Revenue $226M
LTM EBITDA -$581M
$7.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BridgeBio Pharma has a last 12-month revenue of $226M and a last 12-month EBITDA of -$581M.
In the most recent fiscal year, BridgeBio Pharma achieved revenue of $222M and an EBITDA of -$437M.
BridgeBio Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BridgeBio Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $9.3M | $222M | XXX | XXX | XXX |
| Gross Profit | $74.2M | $6.9M | XXX | XXX | XXX |
| Gross Margin | 798% | 3% | XXX | XXX | XXX |
| EBITDA | -$565M | -$437M | XXX | XXX | XXX |
| EBITDA Margin | -6078% | -197% | XXX | XXX | XXX |
| Net Profit | -$481M | -$643M | XXX | XXX | XXX |
| Net Margin | -5172% | -290% | XXX | XXX | XXX |
| Net Debt | $1.3B | $1.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BridgeBio Pharma's stock price is $35.
BridgeBio Pharma has current market cap of $6.6B, and EV of $7.7B.
See BridgeBio Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.7B | $6.6B | XXX | XXX | XXX | XXX | $-3.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BridgeBio Pharma has market cap of $6.6B and EV of $7.7B.
BridgeBio Pharma's trades at 33.9x LTM EV/Revenue multiple, and -13.2x LTM EBITDA.
Analysts estimate BridgeBio Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BridgeBio Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $7.7B | XXX | XXX | XXX |
| EV/Revenue | 34.6x | XXX | XXX | XXX |
| EV/EBITDA | -17.6x | XXX | XXX | XXX |
| P/E | -12.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -14.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBridgeBio Pharma's NTM/LTM revenue growth is 43%
BridgeBio Pharma's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, BridgeBio Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BridgeBio Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BridgeBio Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 2285% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -197% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -154% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 228% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 358% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BridgeBio Pharma acquired XXX companies to date.
Last acquisition by BridgeBio Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . BridgeBio Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BridgeBio Pharma founded? | BridgeBio Pharma was founded in 2019. |
| Where is BridgeBio Pharma headquartered? | BridgeBio Pharma is headquartered in United States of America. |
| How many employees does BridgeBio Pharma have? | As of today, BridgeBio Pharma has 730 employees. |
| Who is the CEO of BridgeBio Pharma? | BridgeBio Pharma's CEO is Dr. Neil Kumar, PhD. |
| Is BridgeBio Pharma publicy listed? | Yes, BridgeBio Pharma is a public company listed on NAS. |
| What is the stock symbol of BridgeBio Pharma? | BridgeBio Pharma trades under BBIO ticker. |
| When did BridgeBio Pharma go public? | BridgeBio Pharma went public in 2019. |
| Who are competitors of BridgeBio Pharma? | Similar companies to BridgeBio Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BridgeBio Pharma? | BridgeBio Pharma's current market cap is $6.6B |
| What is the current revenue of BridgeBio Pharma? | BridgeBio Pharma's last 12-month revenue is $226M. |
| What is the current EBITDA of BridgeBio Pharma? | BridgeBio Pharma's last 12-month EBITDA is -$581M. |
| What is the current EV/Revenue multiple of BridgeBio Pharma? | Current revenue multiple of BridgeBio Pharma is 33.9x. |
| What is the current EV/EBITDA multiple of BridgeBio Pharma? | Current EBITDA multiple of BridgeBio Pharma is -13.2x. |
| What is the current revenue growth of BridgeBio Pharma? | BridgeBio Pharma revenue growth between 2023 and 2024 was 2285%. |
| Is BridgeBio Pharma profitable? | Yes, BridgeBio Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
